北京医学
北京醫學
북경의학
BEIJING MEDICAL JOURNAL
2015年
4期
350-352
,共3页
冠状动脉慢血流%窦性心动过缓%山莨菪碱
冠狀動脈慢血流%竇性心動過緩%山莨菪堿
관상동맥만혈류%두성심동과완%산랑탕감
Coronary slow flow%Sinus bradycardia%Anisodamine
目的:探讨山莨菪碱对冠状动脉慢血流(CSF)伴窦性心动过缓的疗效。方法选择经冠状动脉造影(CAG)证实冠状动脉未见明显狭窄但存在冠状动脉慢血流伴有窦性心动过缓的患者46例,所有患者随机分为试验组、对照组各23例,对照组给予拜阿司匹林100 mg/d、单硝酸异山梨酯缓释片40 mg/d、阿托伐他汀钙40 mg/d,试验组在此基础上加用山莨菪碱10mg 3/d治疗。观察治疗3个月后两组临床症状及心电图(ECG)的改善、对肝肾功能影响及部分患者冠状动脉血流速度的变化。结果试验组改善临床症状有效率及ECG改善优于对照组74.0%vs.52.2%,78.0%vs.52.0%,P均<0.05,肝肾功能治疗前后无明显改变(P>0.05),复查2组CAG冠脉血流帧计数组间比较,试验组(23.72±2.85),对照组(28.46±3.68)具有明显差异。结论山莨菪碱联合基础治疗对CSF伴窦性心动过缓患者具有较好疗效。
目的:探討山莨菪堿對冠狀動脈慢血流(CSF)伴竇性心動過緩的療效。方法選擇經冠狀動脈造影(CAG)證實冠狀動脈未見明顯狹窄但存在冠狀動脈慢血流伴有竇性心動過緩的患者46例,所有患者隨機分為試驗組、對照組各23例,對照組給予拜阿司匹林100 mg/d、單硝痠異山梨酯緩釋片40 mg/d、阿託伐他汀鈣40 mg/d,試驗組在此基礎上加用山莨菪堿10mg 3/d治療。觀察治療3箇月後兩組臨床癥狀及心電圖(ECG)的改善、對肝腎功能影響及部分患者冠狀動脈血流速度的變化。結果試驗組改善臨床癥狀有效率及ECG改善優于對照組74.0%vs.52.2%,78.0%vs.52.0%,P均<0.05,肝腎功能治療前後無明顯改變(P>0.05),複查2組CAG冠脈血流幀計數組間比較,試驗組(23.72±2.85),對照組(28.46±3.68)具有明顯差異。結論山莨菪堿聯閤基礎治療對CSF伴竇性心動過緩患者具有較好療效。
목적:탐토산랑탕감대관상동맥만혈류(CSF)반두성심동과완적료효。방법선택경관상동맥조영(CAG)증실관상동맥미견명현협착단존재관상동맥만혈류반유두성심동과완적환자46례,소유환자수궤분위시험조、대조조각23례,대조조급여배아사필림100 mg/d、단초산이산리지완석편40 mg/d、아탁벌타정개40 mg/d,시험조재차기출상가용산랑탕감10mg 3/d치료。관찰치료3개월후량조림상증상급심전도(ECG)적개선、대간신공능영향급부분환자관상동맥혈류속도적변화。결과시험조개선림상증상유효솔급ECG개선우우대조조74.0%vs.52.2%,78.0%vs.52.0%,P균<0.05,간신공능치료전후무명현개변(P>0.05),복사2조CAG관맥혈류정계수조간비교,시험조(23.72±2.85),대조조(28.46±3.68)구유명현차이。결론산랑탕감연합기출치료대CSF반두성심동과완환자구유교호료효。
Objective To investigate the curative effect of anisodamine on patients with coronary slow flow com-bined sinus bradycardia. Methods A total of 46 patients with coronary slow flow phenomenon combined sinus bradycar-dia but normal coronary angiography were included in this study. They were randomly divided into the experimental group (n=23) and control group(n=23). The control group was treated with aspirin(100 mg/d), isosorbide mononitrate(40 mg/d) and atorvastatin(40mg/d). The experimental group was treated with anisodamine added on the routine treatment. Results The experimental group had a better therapeutic effect than the control group(P<0.05). The hepatorenal function had no significant changes than before treatment(P>0.05). The experimental group was significantly lower than that of the con-trol group(23.72 ± 2.85 vs. 28.46 ± 3.68, P< 0.01). Conclusion Added on the conventional treatment, anisodamine is a good treatment for CSF combined sinus bradycardia.